Company Monitoring Page for Incyte

latest headlines for company on cafepharma

Incyte grabs a new PD-1 checkpoint drug in $900M deal with MacroGenics
Endpoints
Wed, 10/25/17 - 09:44 am
Tags:
Incyte, PD-1 inhibitors, Macrogenics, MGA012
That $1.25B Bristol-Myers IDO1 drug? Incyte claims a former staffer stole it
Endpoints
Sun, 10/15/17 - 01:16 pm
Tags:
Bristol-Myers Squibb, IDO1, Incyte, Flexus
Biotech Firm Incyte Finds The Right Chemistry For Success
Forbes
Tue, 10/10/17 - 10:25 am
Tags:
Incyte, biotech, Jakafi
3 Monster Biotech Stocks in the Making
Motley Fool
Sun, 09/24/17 - 10:24 am
Tags:
biotech, Exelixis, Incyte, Vertex Pharmaceuticals
Incyte’s good week continues with an encouraging update on IDO1 star epacadostat
Endpoints
Thu, 08/31/17 - 10:07 pm
Tags:
Incyte, IDO1, epacadostat, Keytruda, Merck
Incyte, Merck build case for skin cancer combo
BioPharma Dive
Thu, 08/31/17 - 11:42 am
Tags:
Incyte, Merck, Keytruda, advanced melanoma
3 Most Promising Cancer Drugs in Late-Stage Development
Motley Fool
Tue, 08/22/17 - 10:04 am
Tags:
Eli Lilly, abemaciclib, advanced breast cancer, Incyte, epacadostat, Imbruvica, JNJ, prostate cancer
The sector’s most valuable unpartnered assets – up for grabs or on the shelf?
EP Vantage
Tue, 08/22/17 - 09:55 am
Tags:
R&D, Kite Pharma, Incyte, Portola Pharmaceuticals, DBV Technologies, Axovant, AveXis
Tesaro's rumored buyers aren't biting. Should Gilead go for Incyte instead?
Fierce Pharma
Sat, 07/15/17 - 11:14 am
Tags:
Tesaro, Gilead Sciences, Incyte, M&A
Pining for a megadeal, an analyst kicks the tires for another Gilead M&A test drive
Endpoints
Fri, 07/14/17 - 11:28 am
Tags:
M&A, Gilead Sciences, Incyte, Vertex Pharmaceuticals, John Milligan
3 Biotech Stocks That Could Become M&A Targets
Motley Fool
Sat, 06/17/17 - 03:05 pm
Tags:
biotech, M&A, Mallinckrodt, Tesaro, Incyte
Incyte keeps the ASCO spotlight focused on its closely-watched IDO1 drug epacadostat
Endpoints
Mon, 06/5/17 - 10:08 am
Tags:
Incyte, ASCO 2017, epacadostat, non-small cell lung cancer, Keytruda
Prepping for ASCO? Investor Brad Loncar offers his own breakdown of what to watch for
Endpoints
Tue, 05/30/17 - 11:48 am
Tags:
ASCO, IDO inhibitors, CAR-T, PDL-1 inhibitors, Merck, Incyte, NewLink Genetics, Novartis, Juno Therapeutics, Bristol-Myers Squibb
7 Areas to watch from the ASCO abstracts
BioPharma Dive
Fri, 05/19/17 - 11:35 am
Tags:
ASCO 2017, oncology, Incyte, Merck, Eli Lilly, CAR-T, NewLink Genetics, Amgen, Roche, Kite Pharma, Juno Therapeutics
Incyte gets a boost from a series of positive data snapshots for its epacadostat/Keytruda combo
Endpoints
Thu, 05/18/17 - 12:08 am
Tags:
Incyte, epacadostat, ASCO 2017, Merck, Keytruda, non-small cell lung cancer
Incyte doubles down on CEO Hervé Hoppenot’s pay package — big but not stupid
Endpoints
Tue, 04/18/17 - 09:42 am
Tags:
Incyte, Pharma CEOs, Hervé Hoppenot, executive pay
The FDA shot down a new rheumatoid arthritis drug — and the companies that make the drug are tumbling
Yahoo/Business Insider
Mon, 04/17/17 - 11:32 am
Tags:
FDA, rheumatoid arthritis, Eli Lilly, Incyte, baricitinib
Biotech Movers: OncoMed, Incyte, Omeros
TheStreet.com
Mon, 04/17/17 - 11:22 am
Tags:
biotech, OncoMed, tarextumab, small cell lung cancer, Incyte, Eli Lilly, baricitinib, Omeros
Eli Lilly and Incyte say FDA failed to approve their rheumatoid arthritis drug
Marketwatch
Fri, 04/14/17 - 10:48 am
Tags:
Eli Lilly, Incyte, FDA, rheumatoid arthritis, baricitinib
Traders say mergers and acquisitions could bring boost to biotech stocks
CNBC
Fri, 04/14/17 - 10:00 am
Tags:
M&A, biotech, Tesaro, Incyte

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.